| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |